SANTARELLI

Que recherchez-vous ?

Saisissez au moins 2 caractères.

Échap pour fermer

In Biogaran v. Lundbeck (9 October 2026, UPC_CFI_1587/2025), the UPC Milan Central Division examined two late requests: new evidence and validity attacks by Biogaran, and a patent limitation by Lundbeck.

While the revocation action was pending, the EPO Opposition Division issued a preliminary opinion on 6 May 2026.

  1. Additional evidence: refused

    In its subsequent rejoinder, Biogaran introduced five documents, including clinical studies and epidemiological data. Certain new priority objections concerning claims 7 and 9 also relied on the EPO’s opinion.

    Biogaran maintained that the documents merely substantiated its existing arguments or responded to Lundbeck’s submissions. It relied on proportionality, procedural flexibility, fairness and the right to be heard to support their admission.

    The Court first noted that Biogaran had not expressly sought leave to amend its case under Rule 263 RoP. Referring to EOFlow v. Insulet (11 April 2024, UPC_CFI_597/2024), it recalled the front-loaded nature of UPC proceedings and the need to ensure that the opposing party has a proper opportunity to respond (Art. 76 UPCA).

    The Court found that the five documents had been available earlier and supported new lines of attack, rather than merely substantiating existing arguments.

    It further held that the EPO’s preliminary opinion could not justify the late introduction of those attacks before the UPC. The Court therefore refused to admit the new attacks and excluded the five documents insofar as they supported them.

  2. Patent limitation: admitted
    At the oral hearing on 15 September 2026, Lundbeck requested the unconditional deletion of dependent claims 7 and 9, aligning the patent with the amended claim set submitted before the EPO.

    The Court admitted this late request to amend the patent under Rules 30.2, 49.2 and 50.2 RoP. Referring to Meril Italy v. Edwards Lifesciences (UPC CoA, 25 November 2025, UPC_CoA_464/2024 et al.), it noted that the deletion introduced no new technical subject matter, simplified the dispute and required no new validity response from Biogaran.

    The Court also regarded the limitation as a fait accompli, stressing the need for consistency between the patent texts examined before the EPO and UPC.

    Key takeaway: The UPC’s front-loaded procedure does not automatically exclude late submissions. However, late evidence supporting new attacks is difficult to admit when it was already available and its introduction would compromise the opposing party’s right to respond.

    By contrast, this decision shows that a limitation consisting solely of claim deletions may be admitted even at the oral hearing, particularly where it raises no new validity issues for the opposing party.

Stéphanie Garçon, ingénieure brevets chez Santarellli, cabinet de propriété intellectuelle.

Stéphanie Garçon
Ingénieure | CPI

Brevet

Des génériques aux biosimilaires

Drapeau de l'Union Européenne

JUB

Confirmation et extension du concept de « long arm jurisdiction » de la JUB

JUB

JUB (Division Locale de Paris) : première ordonnance autorisant des mesures de conservation de preuves ex-parte !